IKBKE

Across TCGA pan-cancer cohorts, IKBKE Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IKBKE data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IKBKE Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IKBKE expression acts as an unfavorable survival marker.

BLCA, MESO, and LGG are the cancer types where IKBKE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.103	0.480	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LGG	OS	Median	All	0.214	0.889	<.001	6	view →
COAD	DFS	Median	All	0.210	0.696	.011	6	view →
SKCM	DFS	Median	III,IV	0.167	0.653	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IKBKE–BLCA (DFS)

Open the BLCA breakdown →